Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. - Wikidata - wikimedia - TriplyDB

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

http://www.wikidata.org/entity/Q30405991

about

Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease Cerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's Disease Value of cerebrospinal fluid α-synuclein species as biomarker in Parkinson's diagnosis and prognosis An update on the diagnosis and treatment of Parkinson disease Diagnostic Values of Cerebrospinal Fluid T-Tau and Aβ₄₂ using Meso Scale Discovery Assays for Alzheimer's Disease Monitoring of 30 marker candidates in early Parkinson disease as progression markers.The role of biomarkers and imaging in Parkinson's disease.Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity Lewy body dementias.CSF biomarkers and clinical progression of Parkinson disease.Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease.Onset of Mild Cognitive Impairment in Parkinson Disease.Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease prog Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease.Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson's disease patients? A Systematic Review.Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.Review: Parkinson's disease: from synaptic loss to connectome dysfunction.Cognitive decline in Parkinson disease.Plasma α-synuclein predicts cognitive decline in Parkinson's disease.Parkinson disease and cognitive impairment: Five new things.Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.Longitudinal changes in CSF alpha-synuclein species reflect Parkinson's disease progression.Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD.Mild cognitive impairment in Parkinson's disease: a distinct clinical entity?Neural Stem Cells Rescue Cognitive and Motor Dysfunction in a Transgenic Model of Dementia with Lewy Bodies through a BDNF-Dependent Mechanism.Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program.Critical appraisal of pathology transmission in the α-synuclein fibril model of Lewy body disorders.Cognitive and Neuropsychiatric Features in Parkinson's and Lewy Body Dementias.An alpha-synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression.Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

P2860

Q21131066-EC0FF9CA-90BB-4683-A950-0A8B532F60F2 Q26744782-919C6E27-D586-435B-BDC6-3C1F46F30545 Q28082380-6B60C061-DF28-46B1-9C10-8839EB486755 Q30243899-70C43127-C8C9-4D66-AB21-A5B8E234902E Q30659251-ADF74EDD-87FF-4148-8D1F-04A6B1A4F636 Q30783504-9E206640-ECC0-4BFF-BE2F-5528B37D8012 Q31041660-573D41AA-EE6E-40CA-AF87-112979A11D7C Q31097119-8CAF8D3A-FC13-4F3A-A1A6-37B00941225E Q33917300-4582C46B-2FF1-428D-AE19-370623AF77CF Q34460662-C8BB5ECB-3DED-4AC9-BA57-CB603823B2E4 Q34502646-D71290C1-DA7A-471B-96F9-953ED2961A4C Q35106542-5B90D5C4-497E-4B76-AF0E-5E72192EBCF0 Q35597118-DF4AC6E6-BB2D-422B-8020-A267EA4DC91A Q35897340-0495CCA7-5C01-43E9-8F9D-BAA7B0A9CC1C Q35969183-FB1A6A58-1212-49FA-A936-A16FDB342272 Q36118812-92E13A55-400D-4124-8B3E-68C1885C8751 Q36276502-2EF1C967-205D-4F27-A7BD-AF9EFD585272 Q36616565-821D9DAA-C01A-404A-A861-409A5D583979 Q37273088-D87821CD-3F93-4DF1-8D12-7D0D7940196C Q37345484-2278B5D6-988E-48BA-8D6C-09F5B473640D Q37494873-9E8758C2-A6B6-4F6F-BFCD-6870DD1DD536 Q38271572-1345EA2B-31CB-40CE-9777-EBD9EB14DB5A Q38421118-B51CB1FD-7726-477A-AEE2-463116005FD7 Q38603309-B8F86DC4-A41C-4D1E-BFD7-F99A6E15B93F Q38650395-5ADACD5E-6D71-409C-AF9E-EB06C7301F31 Q38751099-FCA0C484-78BD-4E50-931A-0370DE2423C4 Q38760749-84D4DE37-CE8E-4098-8F1D-030CF4F7234F Q39009679-7C4F8F92-AF0E-42DA-ADA1-3EC4C343C273 Q39170813-5E774FB7-D4F4-4B69-8853-4E8AEEEF862E Q39366291-E30F59DE-EAC1-4FE3-AA89-E9C63D9C8DBE Q39466212-8627F2C7-74E9-4F42-8700-D474550E93EB Q40750313-1F55F152-2B9D-4844-91D7-3D8B8180A3B9 Q41152157-436CB074-642D-454E-A5CE-56C076E40E61 Q42181834-3382175B-C91D-4036-83CA-7E9FB2261FC5 Q46012657-E75D1685-28DB-4F34-88E6-DB557F77773E Q47338262-2854284E-3D41-4FBB-A246-847C12935DB7 Q47619917-8751B3F9-2CD0-4424-BBFC-954BB75BDA4C Q47923287-5B2BBCDD-2A30-4046-9F87-917F0F8D8A65 Q47941297-394CF8A1-2BE1-4354-B4A5-D28D3FEE13AD Q48238518-B8DB72A7-BF14-4C55-BDE6-59E1258B305E

P2860

Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

http://www.wikidata.org/entity/Q30405991

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@ast

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@en

type

label

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@ast

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@en

prefLabel

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@ast

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@en

P1433

Q30405991-0A2115B1-3514-4C1B-A8C3-B61E6DB91F92

P1476

Q30405991-01426A11-58BA-44C6-99D7-0392C35A8234

P2093

Q30405991-0AC149B0-80D1-4177-A518-6D6E646E183F

Q30405991-7F6CCFB8-2E3F-4F1D-9FA5-CDC51ACE53AB

Q30405991-938E89B1-FCCF-4E71-B898-4B52D9F1D58E

Q30405991-B2F628F6-0A31-4124-9A90-4EE302A00C1E

Q30405991-B324481F-BEB7-470D-BF82-C57D299296FC

Q30405991-E631C748-7793-448D-B0CD-CBA26CEB0B69

Q30405991-FB44A25F-CBD1-40E6-AE39-EE351C86B4B3

P2860

Q30405991-0D78BBD9-F90B-49FC-82C4-17667D3788AF

Q30405991-172C5AF0-97D8-4A42-8222-0EA8E189B18D

Q30405991-1972A38D-9660-49E9-A2FD-7F39F1C96062

Q30405991-20173D25-EAE1-45CE-B576-E46141EC9C96

Q30405991-30CA1A1C-0759-4F88-AB7C-328AF82D2E04

Q30405991-38910B73-045F-460D-8A2D-5A367BF6DA09

Q30405991-3A6D5A81-B745-43C7-8B17-18E6218607CE

Q30405991-3CD8C177-1AAD-4349-A64D-1ECA0114F118

Q30405991-3F9909D5-5CAD-4EDB-8799-06C2EDCA0E1C

Q30405991-4683BCA7-4A27-4A64-A551-D9CBFD3F4F5D

P304

Q30405991-45047DD7-69DF-4B6E-859F-52467D73147A

P31

Q30405991-F19F87AB-D0DC-4264-997C-002E16D14EE6

P356

Q30405991-94DBF52F-5BE6-440B-9BDD-B97F9E600787

P407

Q30405991-AB1179C6-FC47-4D8F-AEC3-5C3288E63CD9

P433

Q30405991-CEEC2DDC-0995-4269-B65A-BA31673A1542

P478

Q30405991-A376F364-E914-4B3A-8654-6B6DB0B5127C

P50

Q30405991-C04C28C7-BC63-47D4-8FB6-FF783677BB65

Q30405991-DC56F85D-5E87-462F-AFC8-6F6405947D2C

P577

Q30405991-B95385C4-937E-40E6-A14A-EF1B7A58CB25

P698

Q30405991-8C6D7DF9-A1C5-47A2-B6C6-887FD513C2F5

P921

Q30405991-053B88F9-A36B-4787-8D4F-44A760D05C1B

Q30405991-86433537-A18C-4A30-BC54-8D8EB709BA22

Q30405991-CE6D66A7-FE75-4937-921B-76B7C50AFF04

P932

Q30405991-0EA22BFB-FCC8-427C-9235-B47F9A9F4F51

P356

J.AJPATH.2013.12.007

P1433

The American Journal of Pathology

P1476

Cerebrospinal fluid α-synuclei ...... ression in the DATATOP cohort.

@en

P2093

Brenna Cholerton

http://www.w3.org/2001/XMLSchema#string

Carmen Ginghina

http://www.w3.org/2001/XMLSchema#string

Kevin C Cain

http://www.w3.org/2001/XMLSchema#string

Min Shi

http://www.w3.org/2001/XMLSchema#string

Parkinson Study Group DATATOP Investigators

http://www.w3.org/2001/XMLSchema#string

Peggy Auinger

http://www.w3.org/2001/XMLSchema#string

Tessandra Stewart

http://www.w3.org/2001/XMLSchema#string

P2860

Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology

Genome-wide association study reveals genetic risk underlying Parkinson's disease

Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease

Genomewide association study for susceptibility genes contributing to familial Parkinson disease

Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder.

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

α-Synuclein knockout mice have cognitive impairments.

Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy

α-Synuclein oligomers and clinical implications for Parkinson disease.

P304

966-975

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.AJPATH.2013.12.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24625392

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

cerebrospinal fluid

P932

3969999

http://www.w3.org/2001/XMLSchema#string